Complications of type 1 diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 3, 2010, Pages 625-640

  Melendez Ramirez, L Yvonne ^a,b   Richards, Robert J ^a,b   Cefalu, William T ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Complications; Heart disease; Retinopathy; Type 1 Diabetes

Indexed keywords

AMITRIPTYLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DULOXETINE; GABAPENTIN; GLUCOSE; IMIPRAMINE; INSULIN; NORTRIPTYLINE; PREGABALIN; PROKINETIC AGENT; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TRICYCLIC ANTIDEPRESSANT AGENT; VARDENAFIL;

AUTONOMIC NEUROPATHY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LIFESTYLE MODIFICATION; MEDICAL ASSESSMENT; METABOLIC DISORDER; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; MORTALITY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCREENING; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT;

EID: 77955733717     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.05.009     Document Type: Review

References (52)

1. Zhao Y., Ye W., Boye K.S., et al. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities. Diabet Med 2009, 26(1):61-69.
2. Boyle J.P., Honeycutt A.A., Venkat Narayan K.M., et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001, 24:1936-1940.
3. American Diabetes Association Executive summary: standards of medical care in diabetes - 2010. Diabetes Care 2010, 33:S4-S10.
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009, 169(14):1307-1316.
5. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287(19):2563-2569.
6. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
7. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial. Arch Ophthalmol 2008, 126(12):1707-1715.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
9. Degenhardt T.P., Thorpe S.R., Baynes J.W. Chemical modification of proteins by methylglyoxal. Cell Mol Biol 1998, 44:1139-1145.
10. Nakamura S., Makita Z., Ishikawa S., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997, 46:895-899.
11. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
12. Tanaka S., Avigad G., Brodsky B., et al. Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988, 203:495-505.
13. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999, 22:99-111.
14. Kilpatrick E.S., Rigby A.S., Atkin S.L. The diabetes control and complications trial: the gift that keeps giving. Nat Rev Endocrinol 2009, 5:537-545.
15. Lind M., Odén A., Fahlén M., et al. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia 2010, 53(6):1093-1098.
16. American Diabetes Association Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33:S11-S63.
17. Frank R.N. Diabetic retinopathy. N Engl J Med 2004, 350:48-58.
18. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995, 18:258-268.
19. Estacio R.O., McFarling E., Biggerstaff S., et al. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis 1998, 31:947-953.
20. Leske M.C., Wu S.Y., Hennis A., et al. Barbados Eye Study Group. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology 2005, 112:799-805.
21. Klein R., Knudtson M.D., Lee K.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008, 115(11):1859-1868.
22. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
23. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
24. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
25. Preliminary report on the effects of photocoagulation therapy: DRS Report #1. Am J Ophthalmol 1976, 81:383-396. The Diabetic Retinopathy Study (DRS) Research Group.
26. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985, 103:1796-1806.
27. Wong T.Y., Mwamburi M., Klein R., et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009, 32(12):2307-2313.
28. Gross J.L., de Azevedo M.J., Silveiro S.P., et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28(1):164-176.
29. Garg J.P., Bakris G.L. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002, 7:35-43.
30. Klausen K., Borch-Johnsen K., Feldt-Rasmussen B., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004, 110:32-35.
31. Gaspari F., Perico N., Remuzzi G. Measurement of glomerular filtration rate. Kidney Int Suppl 1997, 63:S151-S154.
32. Friedman R., De Azevedo M.J., Gross J.L. Is endogenous creatinine clearance still a reliable index of glomerular filtration rate in diabetic patients?. Braz J Med Biol Res 1988, 21:941-944.
33. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
34. Rigalleau V., Lasseur C., Perlemoine C., et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation?. Diabetes Care 2005, 28:838-843.
35. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167.
36. Boulton A.J., Vinik A.I., Arezzo J.C., et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
37. Vinik A.I., Maser R.E., Mitchell B.D., et al. Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
38. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997, 336:1117-1124.
39. Boulton A.J.M., Malik R.A., Arezzo J.C., et al. Diabetic somatic neuropathies (technical review). Diabetes Care 2004, 27:1458-1486.
40. Boulton A.J.M., Gries F.A., Jervell J.A. Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabet Med 1998, 15:508-514.
41. Rosenstock J., Tuchman M., LaMoreaux L., et al. Pregabalin for the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628-638.
42. Orchard T.J., Olson J.C., Erbey J.R., et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003, 26(5):1374-1379.
43. Forrest K.Y.Z., Becker D.J., Kuller L.H., et al. Are predictors of coronary heart disease and lower extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis 2000, 148:159-169.
44. Erbey J.R., Kuller L.H., Becker D.J., et al. The association between a family history of type 2 diabetes (NIDDM) and coronary artery disease in a type 1 diabetes (IDDM) population. Diabetes Care 1998, 21:610-614.
45. Purnell J.Q., Hokanson J.E., Marcovina S.M., et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA 1998, 280:140-146.
46. Roy M.S., Peng B., Roy A. Risk factors for coronary disease and stroke in previously hospitalized African-Americans with Type 1 diabetes: a 6-year follow-up. Diabet Med 2007, 24(12):1361-1368.
47. Orchard T.J., Costacou T. When are type 1 diabetic patients at risk for cardiovascular disease?. Curr Diab Rep 2010, 10(1):48-54.
48. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
49. Soedamah-Muthu S.S., Chaturvedi N., Witte D.R., et al. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008, 31:1360-1366. EURODIAB Prospective Complications Study Group.
50. Zgibor J.C., Piatt G.A., Ruppert K., et al. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006, 29:1860-1865.
51. Levy A.P., Hochberg I., Jablonski K., et al. Haptoglobin genotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol 2002, 40:1984-1990. Strong Heart Study.
52. Costacou T., Ferrell R.E., Orchard T.J. Haptoglobin genotype and renal disease progression in type 1 diabetes. Diabetes 2008, 57:1702-1706.